 NEWTON, Mass., Nov. 20, 2020 PRNewswire -- Karyopharm Therapeutics Inc. Nasdaq: KPTI, a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported it will present positive results from the Phase 3 portion of the randomized, double blind, placebo... 